Dendreon shareholders strafed the Seattle biotechnology company’s leadership with criticism at Wednesday’s annual meeting, upset at the stock’s 82 percent decline in the past year.
Dendreon shareholders strafed the Seattle biotechnology company’s leadership with criticism at Wednesday’s annual meeting, upset at the stock’s 82 percent decline in the past year.